2,3-Dinor-11β-PGF2α Test

If you have unexplained flushing, hives, gut symptoms, or hard-to-control asthma, you may have heard your immune cells called mast cells blamed. The challenge is that mast cell activity is hard to see on standard labs. This urinary marker is one of the few noninvasive windows into that activity, and it also rises with the kind of low-grade inflammation tied to obesity and metabolic problems.

This is a research-grade test, not a routine clinical screen. Standardized cutpoints do not yet exist, and a single reading should not drive a diagnosis on its own. What it can do is give you a baseline number to track over time, especially if you are working on inflammation, mast cell symptoms, or metabolic health.

What This Marker Actually Measures

2,3-Dinor-11β-PGF2α (2,3-dinor-11-beta-prostaglandin F2-alpha) is a urinary breakdown product of prostaglandin D2 (PGD2), one of the main signaling molecules released by mast cells during allergic and inflammatory reactions. When mast cells fire, they release PGD2, which the body then converts into a series of downstream metabolites that exit through urine. This test picks up one of those downstream metabolites.

Because PGD2 itself breaks down very quickly in blood, measuring its urinary metabolites is a more reliable way to see how much PGD2 your body is producing over a window of time. The test is run using a lab technique called mass spectrometry (a method that identifies molecules by their weight), and the result is reported relative to creatinine in your urine (a way to correct for how concentrated or dilute the sample is).

Mast Cell Activation

Mast cells are immune cells found throughout the body, especially in skin, gut, lungs, and around blood vessels. When they release their contents, PGD2 is one of the major products. The most direct human evidence for this test comes from a pediatric case of mast cell activation syndrome (MCAS), in which urinary 2,3-Dinor-11β-PGF2α was markedly elevated during symptomatic episodes and dropped as symptoms resolved with cromolyn and antihistamine therapy. This pattern supports its use as a noninvasive readout of mast cell activity, though the evidence is limited to case-level data rather than large cohorts.

Severe Asthma and Type 2 Inflammation

In a clinical observational study of 994 children and adults, urinary PGD2 metabolites including 2,3-Dinor-11β-PGF2α were higher in people with severe asthma marked by type 2 inflammation, an immune pattern driven by eosinophils, IgE, and allergic signaling. The metabolite tracked with the underlying inflammatory phenotype rather than with overall asthma severity in a one-to-one way.

In a separate study of 216 adults with severe atopic asthma, urinary 2,3-Dinor-11β-PGF2α was followed as the primary urinary outcome before and after 16 weeks of omalizumab (an anti-IgE biologic). Baseline level and its change did not predict who would benefit clinically. So this marker reflects what mast cells and the PGD2 pathway are doing, but it is not a standalone test for whether a specific biologic will work.

Obesity and Cardiometabolic Risk

In an observational study of 105 overweight and obese subjects, 2,3-dinor oxylipin metabolites including this one were higher in people with obesity and cardiometabolic abnormalities. The authors found that these dinor metabolites tracked more tightly with body mass index than their parent prostaglandins, suggesting they may be a better readout of low-grade inflammation related to body composition. Dietary antioxidant intake was inversely linked to these metabolites, meaning people eating more antioxidant-rich foods tended to have lower levels.

What This Marker Does Not Tell You

This test does not diagnose any specific disease on its own. In the largest treatment study using it as the primary urinary outcome, it did not separate clinical responders from non-responders to omalizumab better than a coin flip. It also has not been shown in published data to identify early disease in asymptomatic people, change clinical management in healthy adults, or improve outcomes beyond standard biomarkers. Use it as one input in a panel, not as a standalone verdict.

Reference Ranges

There are no standardized clinical cutpoints for 2,3-Dinor-11β-PGF2α. Published studies report values from research populations using specialized mass spectrometry methods, and labs use different assays and reporting units, so absolute numbers vary. The most useful interpretation strategy is to establish your personal baseline and track changes within the same lab over time, rather than comparing your single value to a universal threshold.

What is observable across studies is a general direction. Levels tend to be higher in people with active mast cell activation, severe type 2 asthma, obesity, or systemic inflammatory challenges, and tend to be lower in people consuming antioxidant-rich diets or responding to anti-inflammatory therapies. Treat your own number as a starting point on a trend line.

Tracking Your Trend

Because this is a research-grade marker without fixed thresholds, a single reading carries limited interpretive weight. Serial measurements are far more informative. They let you see whether your level is moving up, moving down, or staying stable in response to interventions you are making.

A reasonable approach is to get a baseline, then retest in 3 to 6 months if you are making meaningful changes like adding an anti-inflammatory diet, treating suspected mast cell activation, or losing weight. After that, at least annual testing is sensible if you are using this marker as part of a longevity or inflammation-focused workup. If your goal is to track an intervention specifically, retest after enough time has passed for a sustained biological effect, not just days after starting something new.

What an Abnormal Result Should Prompt

An elevated value is not a diagnosis. It is a flag that warrants context. If your level is high and you have symptoms suggesting mast cell involvement (flushing, hives, unexplained anaphylaxis-like episodes, gut symptoms), this is worth discussing with an allergist or immunologist who can order companion markers and consider conditions like mast cell activation syndrome or mastocytosis. If your level is high alongside a known type 2 asthma diagnosis, it adds to the picture of active inflammation and may be discussed with a pulmonologist.

If you have no symptoms but a high level shows up alongside obesity, insulin resistance, or other cardiometabolic concerns, it points toward systemic inflammation as a treatment target rather than a specific disease to chase. The decision pathway here is to treat the underlying driver (body composition, diet quality, metabolic health) and retest to confirm the marker moves in the right direction.

When Results Can Be Misleading

This biomarker is sensitive to acute and short-term influences that can distort a single reading. Use the following considerations to time your sample thoughtfully.

• Acute inflammatory events: systemic inflammation from infection or bacterial endotoxin exposure raises urinary 2,3-Dinor-11β-PGF2α. If you have been acutely ill, wait until you have fully recovered before testing.
• Niacin flushing: taking niacin (vitamin B3) at flushing doses triggers a sharp PGD2 release and elevates this metabolite acutely. If you use niacin, time your test away from doses.
• Sample concentration: urine that is unusually dilute or concentrated can shift the raw number. Labs correct for this by normalizing to creatinine, but extreme hydration states can still affect results.
• Assay differences: mass spectrometry methods vary between labs, so the same urine sample can read differently at different facilities. Stay with one lab when tracking your trend.

How This Fits Into a Larger Workup

This marker is most informative as part of a panel rather than alone. In mast cell evaluations, it is often run alongside other mediator markers like urinary N-methylhistamine and serum tryptase. In asthma and inflammation contexts, it pairs with markers of type 2 immunity. In a longevity or preventive framing, it complements broader inflammation markers like hs-CRP (high-sensitivity C-reactive protein), giving you a different angle on what is driving inflammatory tone.